Key facts
- VitaDX’s last known valuation is $18.0M (Sep 2020).
- It has raised $30.1M; the latest was Later Stage VC ($1.8M) in Aug 2025.
- Notable investors include Bpifrance, GO Capital, Odyssee Venture, Caisse d'Epargne, Banque Populaire Grand Ouest — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for VitaDX
- ·The full record, as it builds
Funding rounds
No funding rounds for VitaDX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VitaDX
Developer of medical devices designed to identify the early stage of bladder cancer in patients. The company's devices use fluorescence imaging and machine learning to explore the urinary excretory tract to detect potential bladder abnormalities, enabling doctors to offer cancer diagnostic services for earlier detection of bladder cancer which can lead to effective treatment and better outcomes for patients.
- Sector
- Healthcare
- HQ
- Rennes, France
- Founded
- 2014
- Employees
- 25
- Website
- vitadx.com/
- Ownership
- Privately Held (backing)
VitaDX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VitaDX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VitaDX in its N-PORT filings yet. We sweep new filings monthly.